← Leaderboards
Mervyn J Monteiro
University Of Maryland Baltimore
$14,914,800
Attributed
$14,914,800
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,914,800 · 9
By mechanism
R01$11,444,699 · 5
RF1$2,200,770 · 1
R21$1,269,331 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Paul A Welling$21,115,168
- J. Marc Simard$20,591,919
- Giuseppe Inesi$4,801,709
- Martin F Schneider$21,777,769
- Sai Sachin Divakaruni$162,284
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsCellsDefectLeadNeurodegenerative DisordersPathway InteractionsUbiquilinMulticatalytic Endopeptidase ComplexAutophagocytosisHuman DiseaseMutationMouse ModelAmyotrophic Lateral SclerosisMutantTransgenic MiceAnimalsPathogenesisProtein DegradationInsightLinkNeuronsCognitive DeficitsMotor Neuron DiseaseGenes
Grant awards (40)
Mechanistic studies and therapeutics for ALS/FTD linked to UBQLN2 mutations$738,305
R01 · FY2025 · NS · contact PI
Mechanistic studies and therapeutics for ALS/FTD linked to UBQLN2 mutations$2,200,770
RF1 · FY2022 · NS · contact PI
Deciphering the role of ER stress in ALS pathogenesis caused by UBQLN2 mutations$547,956
R01 · FY2021 · NS · contact PI
Mechanistic studies and therapeutics for ALS-FTD linked to UBQLN2 mutations$504,381
R01 · FY2021 · NS · contact PI
Deciphering the role of ER stress in ALS pathogenesis caused by UBQLN2 mutations$547,956
R01 · FY2020 · NS · contact PI
Mechanistic studies and therapeutics for ALS-FTD linked to UBQLN2 mutations$504,381
R01 · FY2020 · NS · contact PI
Deciphering the role of ER stress in ALS pathogenesis caused by UBQLN2 mutations$547,956
R01 · FY2019 · NS · contact PI
Mechanistic studies and therapeutics for ALS-FTD linked to UBQLN2 mutations$504,381
R01 · FY2019 · NS · contact PI
Deciphering the role of ER stress in ALS pathogenesis caused by UBQLN2 mutations$547,956
R01 · FY2018 · NS · contact PI
Mechanistic studies and therapeutics for ALS-FTD linked to UBQLN2 mutations$504,381
R01 · FY2018 · NS · contact PI
Quality control of APP cleavage by RING-finger ubiquitin ligases$193,125
R21 · FY2018 · AG · contact PI
Deciphering the role of ER stress in ALS pathogenesis caused by UBQLN2 mutations$547,956
R01 · FY2017 · NS · contact PI
Mechanistic studies and therapeutics for ALS-FTD linked to UBQLN2 mutations$503,564
R01 · FY2017 · NS · contact PI
Quality control of APP cleavage by RING-finger ubiquitin ligases$231,750
R21 · FY2017 · AG · contact PI
Generation of a mouse model to monitor ERAD in neurons$193,125
R21 · FY2017 · NS · contact PI
Generation of a mouse model to monitor ERAD in neurons$231,125
R21 · FY2016 · NS · contact PI
Validation of ubiquilin for Huntingtons disease$189,956
R21 · FY2014 · NS · contact PI
Validation of ubiquilin for Huntingtons disease$230,250
R21 · FY2013 · NS · contact PI
Functional Studies of Ubiquilin$301,381
R01 · FY2011 · GM · contact PI
Functional Studies of Ubiquilin$304,425
R01 · FY2010 · GM · contact PI
Functional Studies of Calmyrin$157,454
R01 · FY2009 · AG · contact PI
Functional Studies of Ubiquilin$154,132
R01 · FY2009 · GM · contact PI
Functional Studies of Ubiquilin$153,369
R01 · FY2009 · GM · contact PI
Functional Studies of Calmyrin$125,423
R01 · FY2009 · AG · contact PI
Functional Studies of Ubiquilin$307,500
R01 · FY2008 · GM · contact PI
Functional Studies of Calmyrin$282,877
R01 · FY2008 · AG · contact PI
Functional Studies of Calmyrin$288,651
R01 · FY2007 · AG · contact PI
Functional Studies of Ubiquilin$96,674
R01 · FY2007 · GM · contact PI
Functional Studies of Calmyrin$297,271
R01 · FY2006 · AG · contact PI
Functional Studies of Ubiquilin$287,120
R01 · FY2006 · GM · contact PI
Functional Studies of Calmyrin$304,425
R01 · FY2005 · AG
Functional Studies of Ubiquilin$294,030
R01 · FY2005 · GM
Functional Studies of Ubiquilin$294,030
R01 · FY2004 · GM
FUNCTION OF ALZHEIMER DISEASE PRESENILIN 2$263,344
R01 · FY2004 · AG
Functional Studies of Ubiquilin$294,030
R01 · FY2003 · GM
FUNCTION OF ALZHEIMER DISEASE PRESENILIN 2$255,672
R01 · FY2003 · AG
FUNCTION OF ALZHEIMER DISEASE PRESENILIN 2$248,225
R01 · FY2002 · AG
FUNCTION OF ALZHEIMER DISEASE PRESENILIN 2$240,996
R01 · FY2001 · AG
FUNCTION OF ALZHEIMER DISEASE PRESENILIN 2$255,827
R01 · FY2000 · AG
NEUROFILAMENT KINASES$238,670
R01 · FY2000 · AG